BioNet News, Press Releases 17 Dec 2022 Pharmaniaga and BioNet Sign Research Collaboration Agreement for Children’s Hexavalent Vaccine KUALA LUMPUR, 13 DECEMBER 2022 – Pharmaniaga LifeScience Sdn Bhd (PLS), a wholly-owned subsidiary of Malaysia's leading pharmaceutical company, Pharmaniaga… Supachai
BioNet News, Press Releases 08 Dec 2022 INFECTIOUS AND EMERGING DISEASES: A BIOCLUSTER PROJECT IN OCCITANIA Toulouse, Lyon and Bangkok, 8th December 2022 - Within the framework of the "BIOCLUSTER" Call for Expressions of Interest of… Supachai
BioNet News, Press Releases 28 Nov 2022 BioNet CEO discussed with French President Emmanuel Macron during APEC in Bangkok. Bangkok, 28th November 2022 - French President Emmanuel Macron took the opportunity of his attendance to the Thailand-hosted Asia Pacific… Supachai
BioNet News, Covid-19, Press Releases 16 Nov 2022 Phase 2 trial of ChulaCov19 BNA159 mRNA Vaccine to start in Australia ChulaCov19 BNA159 is a COVID-19 mRNA vaccine developed by Chulalongkorn University and produced by BioNet ChulaCov19 mRNA vaccine was found… Supachai
BioNet News, Pertussis 17 Jun 2022 Etude Pertagen® 2xÉTUDE SUR PERTAGEN®, UN NOUVEAU VACCIN CONTRE LA COQUELUCHE Statut En cours de recrutement. La coqueluche circule largement chez les jeunes, qui jouent un rôle de réservoir et transmettent… Supachai
BioNet News, Covid-19, Press Releases 21 Mar 2022 Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines. Supachai
BioNet News, Pertussis 26 Feb 2022 Pharmaniaga And Thailand’s BioNet Group Collaborate In Vaccine R&D Pharmaniaga Berhad is looking to collaborate and partner with Thailand’s BioNet Group for vaccine research and development (R&D) and Bio-Innova… Supachai
BioNet News, Covid-19 01 Feb 2022 BioNet earns up to $16.9M from CEPI for studies, production and analysis of variant-proof SARS-CoV-2 vaccine Drawing from a $200 million program meant to stimulate the development of vaccines with broad betacoronavirus protection, the Coalition for… Supachai
BioNet News, Covid-19 26 Jan 2022 CEPI partners with BioNet to expand variant-proof vaccine programme OSLO, Norway, 25 January 2022: CEPI, the Coalition for Epidemic Preparedness Innovations, today announced the latest award under its $200m programme, launched… Supachai
BioNet News, Covid-19, Press Releases 18 Jan 2022 COVALIA study update: Interim Safety Results from needle-free SARS-CoV2 DNA vaccine phase 1 trial Melbourne 17 January 2022 –Technovalia, an Australian biotech vaccine developer today announced the interim safety results of the ongoing phase… Supachai